Innovative Cancer Drugs Ambagon Therapeutics is focused on developing small molecule cancer drugs targeting oncogenic proteins, creating potential sales opportunities for oncology treatment providers and research institutions.
Expansion and Partnerships Through partnerships and collaborations with institutes like Eindhoven University of Technology, Ambagon Therapeutics is expanding its treatment therapies based on proteins, indicating potential opportunities for joint ventures or technology licensing.
Stable Funding and Growth With recent financing of $85 million and a revenue range of $0 - 10 million, Ambagon Therapeutics demonstrates financial stability and growth potential, offering sales opportunities for financing services and investment partnerships.
Platform Approach for Clinical Needs Ambagon's innovative platform approach targets major unmet clinical needs beyond oncology, presenting opportunities for partnerships with healthcare providers and biotech companies seeking novel therapeutic solutions.
Development of Novel Therapeutic Candidates By focusing on developing novel therapeutic candidates for difficult-to-drug proteins, Ambagon Therapeutics opens doors for collaboration with companies specializing in drug development and personalized medicine.
139
$10M$50M
381$10M$50M
570$50M$100M
84$10M$50M
128$10M$50M
74$10M$50M
24$10MAmbagon Therapeutics uses 8 technology products and services including Font Awesome, Google Cloud, jQuery, and more. Explore Ambagon Therapeutics's tech stack below.
| Ambagon Therapeutics Email Formats | Percentage |
| FLast@ambagontx.com | 49% |
| First@ambagontx.com | 1% |
| First-Last@ambagontx.com | 1% |
| FLast@ambagontx.com | 49% |
Biotechnology ResearchCalifornia, United States11-50 Employees
Ambagon is discovering and developing small molecule cancer drugs that stabilize the direct interaction of oncogenic proteins with the 14-3-3 class of adaptor proteins. Ambagon’s platform approach will open opportunities to address major unmet clinical needs beyond oncology.
Company Overview
Media & News
Funding & FinancialsAmbagon Therapeutics has raised a total of $45M of funding over 3 rounds. Their latest funding round was raised on May 27, 2022 in the amount of $45M.
Ambagon Therapeutics's revenue is in the range of $10M
Funding & FinancialsAmbagon Therapeutics has raised a total of $45M of funding over 3 rounds. Their latest funding round was raised on May 27, 2022 in the amount of $45M.
Ambagon Therapeutics's revenue is in the range of $10M
1-888-653-2347 
support@leadiq.com